Bavarian Nordic A/S
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Bavarian Nordic A/S
With the integration with new parent LG Chem having gone "smoothly," AVEO Oncology is accelerating R&D efforts by beginning a pivotal Phase III trial with a combination of its novel candidate for head and neck cancer.
Evaluate’s fourth quarter data show that biopharma venture capital fundraising fell from $4.28bn in in Q3, but there was a rise in smaller deals and financial market conditions are poised for a turnaround.
The group’s second major venture round this year makes it one of the most successful fundraisers of 2023.
Safety signals were the most common cause of discontinued candidates in the breakthrough therapy designation program in 2023.
- Large Molecule
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.